Selective Serotonin Reuptake Inhibitors (SSRIs) Market by Application and Geography - Forecast and Analysis 2021-2025

The selective serotonin reuptake inhibitors (SSRIs) market size has the potential to grow by USD 809.73 million during 2021-2025, and the market’s growth momentum will accelerate at a CAGR of 4%. 

This report provides a detailed analysis of the market by application (depression, anxiety and panic disorder, and other mental conditions), geography (North America, Europe, Asia, and ROW), and key vendors. 

Market Overview

Browse TOC and LoE with selected illustrations and example pages of Selective Serotonin Reuptake Inhibitors (SSRIs) Market

 Request a FREE sample now!

Market Competitive Analysis

The report analyzes the market’s competitive landscape and offers information on several market vendors, including: 

 

• AbbVie Inc.
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Cipla Inc.
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• H. Lundbeck AS
• Lupin Ltd.
• Pfizer Inc.
• Takeda Pharmaceutical Co. Ltd.

 

The selective serotonin reuptake inhibitors (SSRIs) market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market. Click here to uncover other successful business strategies deployed by the vendors. 

The market players also significantly leverage external market drivers such as rising prevalence of mental illnesses to achieve growth opportunities. However, factors such as side effects of antidepressants will challenge the growth of the market participants. To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Download a free sample of the selective serotonin reuptake inhibitors (SSRIs) market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

This selective serotonin reuptake inhibitors (SSRIs) market analysis report also provides detailed information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities. 

Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Key Drivers and Trends

The rising prevalence of mental illnesses is one of the key factors driving the sales of SSRIs drugs. With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. The number of vendors manufacturing these drugs is increasing.  Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder.

Growing geriatric population will also drive the growth of the market. Mental disorders are significant among individuals with comorbidities such as heart conditions and cancer.  The majority of the geriatric population suffers from the mentioned health conditions.  The geriatric population across the world is at the highest risk of developing mental disorders compared with the adult population. The rising awareness of depression among the geriatric population and the healthcare providers and the increasing availability of SSRI treatment regimes for such patients are supporting the growth of the market.

 

Grab your Free Sample now to unlock further information on other key market drivers

Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Segmentation by Geography

For more insights on the market share of various regions Request for a FREE sample now!

41% of the market’s growth will originate from North America during the forecast period. The US is one of the key markets for selective serotonin reuptake inhibitors (SSRIs) in North America. Market growth in this region will be slower than the growth of the market in Asia.

The presence of many pharmaceutical companies that offer both branded and generic SSRIs drugs is one of the prime factors that will facilitate the selective serotonin reuptake inhibitors (SSRIs) market growth in North America over the forecast period. To garner further competitive intelligence and regional opportunities in store for vendors, view our sample report. 

Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Segmentation by Application

Request for a FREE sample and Get more information on the market contribution of various segments

The incidence of depression has been increasing across the globe. Serotonin levels have a direct correlation with depression. A drop in the serotonin level indicates depression. Therefore, pharmaceutical companies have formulated SSRIs drugs that can inhibit 5-hydroxytryptamine (5-HT) reuptake transporters to increase the serotonin concentration at the synaptic cleft. Also, SSRIs drugs are better absorbed in gastrointestinal tracts compared with other antidepressants. The growth of the market segment is expected to be significant during the forecast period.

Fetch actionable market insights on post COVID-19 impact on each segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the selective serotonin reuptake inhibitors (SSRIs) market size.

 

Request for a FREE sample

Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Key Highlights of the Report for 2021-2025

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive selective serotonin reuptake inhibitors (SSRIs) market growth during the next five years
• Precise estimation of the selective serotonin reuptake inhibitors (SSRIs) market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the selective serotonin reuptake inhibitors (SSRIs) industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of selective serotonin reuptake inhibitors (SSRIs) market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Selective Serotonin Reuptake Inhibitors (SSRIs) Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 4%
Market growth 2021-2025	$ 809.73 million
Market structure	Fragmented
YoY growth (%)	3.15
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 41%
Key consumer countries	US, Germany, China, UK, and France
Competitive landscape	Leading companies, competitive strategies, consumer engagement scope
Companies profiled	AbbVie Inc., Apotex Inc., Aurobindo Pharma Ltd., Cipla Inc., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Lupin Ltd., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Market Dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.